Connect to other sites within the UBM Medica Network
EZH2 May Be Required for CML Initiation, Could Represent Therapeutic Target
A study found that the protein EZH2 is required for chronic myeloid leukemia initiating cells to survive. Inhibiting EZH2 could improve outcomes in TKI-resistant disease.
EUTOS Registry Shows Good CML Outcomes Outside Trials
Data from the large, population-based EUTOS registry showed strong survival outcomes in patients with CML, and validated risk scores as prognostic of outcome.
Nilotinib, Dasatinib Offer Similar Outcomes in CML Patients
A propensity score–matched comparison of two phase II trials found that dasatinib and nilotinib offer similar responses and outcomes as first-line therapy for patients with chronic-phase CML.
ABCB1 mRNA Could Predict TKI Response in CML
Early evaluation of ABCB1 mRNA expression may help identify CML patients who are likely to be resistant to first- and second-generation tyrosine kinase inhibitors.
Post-Transplant TKI Maintenance Yields Promising Results in High-Risk CML, ALL
Maintenance therapy with TKIs following allogeneic HSCT is feasible and may improve outcomes in patients with high-risk Philadelphia chromosome–positive leukemia.
Life Expectancy in CML Patients Approaching General Population’s
A study covering 4 decades of patients with chronic myeloid leukemia in Sweden found dramatic improvements in life expectancy since the advent of tyrosine kinase inhibitor therapy.
CML Patients on TKIs May Have Increased Risk of Thromboembolic Events
Patients with chronic myeloid leukemia who are treated with tyrosine kinase inhibitors could be at increased risk of long-term cardiovascular toxicity.
By clicking Accept, you agree to become a member of the UBM Medica Community.